Salvatore Privitera Sells 7,763 Shares of AtriCure (NASDAQ:ATRC) Stock

AtriCure, Inc. (NASDAQ:ATRC) insider Salvatore Privitera sold 7,763 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $52.50, for a total value of $407,557.50. Following the sale, the insider owned 150,921 shares of the company’s stock, valued at approximately $7,923,352.50. This represents a 4.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

AtriCure Stock Performance

Shares of NASDAQ ATRC opened at $51.52 on Friday. The business’s 50-day moving average price is $40.10 and its two-hundred day moving average price is $32.83. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. AtriCure, Inc. has a one year low of $25.36 and a one year high of $53.50. The company has a market capitalization of $2.62 billion, a P/E ratio of 245.35 and a beta of 1.26.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The company had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period last year, the business earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Analysts anticipate that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On AtriCure

A number of institutional investors have recently modified their holdings of ATRC. AQR Capital Management LLC boosted its holdings in shares of AtriCure by 1.0% during the 1st quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock worth $2,700,000 after buying an additional 837 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in AtriCure by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock worth $908,000 after acquiring an additional 1,230 shares during the period. Goldman Sachs Group Inc. lifted its position in AtriCure by 1.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock worth $27,830,000 after acquiring an additional 8,956 shares during the last quarter. Jane Street Group LLC lifted its position in AtriCure by 658.3% during the 1st quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company’s stock worth $3,254,000 after acquiring an additional 87,553 shares during the last quarter. Finally, Strs Ohio acquired a new position in AtriCure during the 1st quarter worth $158,000. Institutional investors own 99.11% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ATRC shares. Raymond James Financial set a $52.00 target price on shares of AtriCure in a research note on Tuesday, July 21st. Weiss Ratings upgraded shares of AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 19th. Piper Sandler lifted their price objective on shares of AtriCure from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, August 27th. BTIG Research upped their price objective on shares of AtriCure from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, August 24th. Finally, Citigroup reiterated a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, AtriCure currently has an average rating of “Moderate Buy” and an average target price of $52.00.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.